

IMMUNOLOGICAL MEMORY IN VITRO*

BY GORDON N. RADCLIFFE,† M.D., AND MICHAEL A. AXELRAD, M.D.

(From the Department of Pathology, Queen's University, Ontario, and the Kingston General Hospital, Kingston, Ontario, Canada)

(Received for publication 4 November 1970)

A suitable initial exposure of an individual to an antigen typically results in the development of a specific and persisting altered reactivity manifested by facilitation of subsequent responses to that antigen. Components of such facilitation characteristically include a heightened response, earlier appearance of a detectable response, more rapid development of peak values, the capacity to respond in the presence of specific antibody, and, in the case of antibody responses, parallel production of IgM and IgG immunoglobulins (1-5). These features have been chiefly delineated by *in vivo* studies and the purpose of the present work was to examine the extent to which they occur *in vitro*.

Materials and Methods

Mice.—Female DBA/2 mice (Jackson Laboratories, Bar Harbor, Maine) 10 wk of age or older provided mouse spleen cell suspensions (MSC).¹ Mice receiving *in vivo* immunization were matched for age with nonimmunized controls. Swiss white mice were the source of mouse sera.

Antigen.—Sterile, washed sheep erythrocytes (SRBC) from one male gelding were used throughout.

Sera.—Late immune anti-SRBC serum was pooled from 200 mice receiving 3×10^8 SRBC intraperitoneally 8 and 3 wk before sacrifice. The pooled serum had a 2-mercaptoethanol-insensitive hemagglutinin titer of 1:640. Early (IgM) anti-SRBC serum was pooled from 50 mice sacrificed 3 days after receiving 3×10^8 SRBC intraperitoneally. The serum had a hemagglutinin titer of 1:32 which was abolished by 2-mercaptoethanol. Normal mouse serum was pooled from 50 nonimmunized mice. All mouse sera were warmed to 56°C for 30 min, sterilized by ultrafiltration, and then stored in frozen portions. Fetal calf serum was supplied by Reheis Chemical Co. (Division of Armour Pharmaceutical), Chicago, Ill. Guinea pig serum was lyophilized when fresh and used after reconstitution at a dilution of 1:8 as the source of complement. Rabbit anti-mouse IgG serum was prepared from rabbits immunized with immuno-

* This study was supported by grant MA-3153 from the Medical Research Council of Canada.

† Present address: Department of Pathology, Veterans' Administration Hospital, 1055 Clermont Street, Denver, Colo. 80220.

¹ *Abbreviations used in this paper:* MSC, mouse spleen cells; NMS, normal mouse serum; PFC, plaque-forming cells; SRBC, sheep erythrocytes.

electrophoretically-pure mouse IgG. Lyophilized portions were reconstituted and used at a working dilution of 1:20.

Immunization.—(a) In vivo: SRBC dose was 1.5×10^8 intravenously. Passive immunization comprised 0.2 ml. of intravenous late-immune serum. (b) In vitro: Routinely cultures (except negative controls) received 2.5×10^6 SRBC. Cultures passively immunized received 5 μ l of late-immune serum.

Culture Technique.—Each culture (1 ml total volume) contained 1×10^7 mouse spleen cells prepared, maintained, and given daily nutritional additive, in the manner described by Mishell and Dutton (6). Media were supplied by Grand Island Biological Company, Grand Island, N. Y.

Assay.—Cultures were assayed for direct and, using the anti-mouse IgG developing serum, for indirect plaque-forming cells (PFC) by a slide-modification of techniques previously described (7, 8). Slides were incubated for $\frac{1}{2}$ hr before exposure to complement or complement-developing-serum mixture for a further $1\frac{1}{2}$ hr.

RESULTS

Characterization of the Immune State.—Spleen cell cultures were prepared from matched groups of donors at various times after injection of 1.5×10^8 SRBC intravenously. The 4 day in vitro response to SRBC was then assayed. The results, for both direct (IgM-producing) and indirect (IgG-producing) PFC are summarized in Fig. 1.

Cultures did not produce detectable numbers of indirect PFC until the donor animals were more than 1 wk post-in vivo immunization. (This was in contrast to the indirect PFC activity induced by the in vivo immunization in the donor spleens, where peak values occurred on about the 6th day of the in vivo primary response and had fallen to less than 10% of this level by day 10.) In vitro responses were greatly augmented about 3 days after in vivo immunization. This degree of augmentation declined over the next 5 wk to a fairly stable level, only slightly above responses of cultures from nonimmunized mice. Mice which were 8 or more wk post-SRBC immunization had passed into this stable phase and were termed "late-immune." Such mice no longer produced detectable numbers of indirect PFC in vitro (Fig. 1). The in vivo response of these mice was however characterized by an early and predominant appearance of indirect PFC as well as by resistance to suppression by antibody, and was invariably distinguishable from the initial in vivo response of previously nonimmunized mice, as seen in a typical experiment whose results are shown in Table I. The suggestion that the in vitro response of late-immune mice resembled the response of nonimmune mice was further evaluated.

Effect of Varying In Vitro Antigen Dose.—Routinely 2.5×10^6 SRBC were added to each culture. Over a 64-fold range around this dose, responses of both late-immune- and nonimmune-derived cultures were similarly and relatively slightly augmented in the presence of increasing doses of antigen (Fig. 2).

This parallel behavior of the two groups suggested that the consistently

greater responses of late-immune-derived cultures do not reflect a significant change in the composition or properties of the responding cell populations.




FIG. 1. Effect of in vivo immunization (1.5×10^8 SRBC by vein) on the in vitro response. Each point represents the mean of two to four experiments in each of which the mean of 6–12 cultures was determined. The first point (left) represents responses after no SRBC in vivo. Days indicated are those on which the cultures were started.

TABLE I
Primary and Secondary In Vivo PFC Response of DBA/2 Mice. Effects of Passive Immunization with Late Immune Serum

SRBC (Days before assay)*	Anti-SRBC†	PFC/spleen‡	
		Direct	Indirect
4	0	67,550	18,250
4	+	650	NIL
60	0	400	NIL
60 and 2	0	1,200	5,600
60 and 4	0	9,100	136,350
60 and 4	+	2,700	63,400

* Groups of eight mice; each immunization 1.5×10^8 SRBC intravenously.

† 0.2 ml of late-immune serum 6 hr before last injection SRBC; 0 indicates no passive immunization.

‡ Group means rounded to the nearest 50.

Effect of Varying Spleen Cell Concentration.—At the MSC concentration routinely employed (1×10^7 /ml) efficiency of the response (expressed as PFC/ 10^6 MSC cultured) was close to maximum and unaffected by small variations of MSC concentration. Considerable reduction in the MSC concentration re-

sulted in a rapidly declining efficiency of response. The regression curves obtained for the variation of efficiency with MSC concentration were similar for late-immune- and nonimmune-derived cultures, showing a consistent and fairly uniform vertical displacement over a wide range of concentration (Fig. 3). This




FIG. 2. Comparative in vitro dose-response curves for spleen cell cultures derived from late-immune and nonimmune donor mice. Assays are for direct PFC and each point represents the mean of five cultures.




FIG. 3. Relative efficiency of responses from late-immune and nonimmune derived cultures over a range of spleen cell concentrations. Assays enumerate direct PFC and each point represents the mean of five cultures.

again suggested that the higher responses of late-immune-derived cultures were not based on a significant change in the composition or properties of the responding system.

Dependence on Separable Cell Types.—The primary in vitro immune response to SRBC is dependent on the interaction of at least two behaviorally distinct cell populations. Mosier (9) settled MSC suspensions on plastic surfaces and was able to separate a subpopulation of cells adherent to the surface from one containing the nonadherent cells. Such subpopulations were singly essentially incapable of producing in vitro PFC responses but regained this ability when recombined. We found the response of MSC suspensions from late-immune mice

TABLE II
Secondary Immune Response In Vitro. Dependence on Adherent and Nonadherent Cell Types

Cells cultured*	SRBC†	PFC/culture‡
L.R.	+	815
L.R.	0	— 4
M.R.	+	0
M.R.	0	0
L.R. + M.R.	+	5540
L.R. + M.R.	0	290

* L.R. indicates nonadherent (lymphocyte-rich) cells at 1×10^7 cells/culture. M.R. indicates adherent (macrophage-rich) cells at 1×10^6 cells/culture.

† 0 indicates no SRBC added to cultures.

‡ Mean of duplicate assays of three to six cultures.

was similarly dependent on adherent and nonadherent subpopulations (Table II).

Effect of Anti-SRBC Antibody.—MSC suspensions from nonimmune mice differed from immune suspensions in not having been exposed to anti-SRBC antibody in vivo. The effect of such exposure was therefore tested by comparing the in vitro responses of normal nonimmune suspensions with that of suspensions from nonimmune donors which had been given 0.2 ml of late-immune anti-SRBC serum 24 hr before sacrifice. The results (Table III) indicated that in vivo exposure to a quantity of antibody sufficient to prevent the in vivo primary response did not affect a subsequent response in vitro.

The addition of either early (IgM) mouse anti-SRBC serum (diluted to give a final hemagglutinin titer in the culture of 1:1) or late-immune mouse anti-SRBC (predominantly IgG, 5 μ l added to 1 ml of culture for a final hemagglutinin titer of 1:2) inhibited the PFC responses of both nonimmune and late-immune spleen suspensions. Normal mouse serum (NMS) absorbed with SRBC was similarly diluted and added to other cultures as a control. Such NMS, as well as late-immune serum absorbed with SRBC and added to cultures in the

TABLE III
In Vivo Passive Immunization. Effects on In Vivo and In Vitro Primary Responses Compared

In vivo anti-SRBC*	SRBC‡		PFC/10 ⁶ spleen cells§	
	In vivo	In vitro	In vivo	In vitro
0	+		871	
0		+		262
+	+		12	
+		+		215

* + indicates 0.2 ml of late immune serum intravenously 24 hr before active immunization. 0 indicates no passive immunization.

‡ 1.5 × 10⁸ intravenously or 2.5 × 10⁶ in vitro.

§ Direct PFC. Means of five mice or duplicate assays of five cultures; all assays 4 days after active immunization.

TABLE IV
Effect of In Vitro Passive Immunization and In Vivo Active Immunization on In Vitro Responses

In vivo SRBC* at time before culture	In vitro anti-SRBC‡	In vitro SRBC§	Duration of culture	In vitro response (PFC/culture)	
				Direct	Indirect
(days)			(days)		
None given	0	+	4	1,869	0
None given	+	+	4	12	0
None given	0	0	4	14	0
3	0	+	4	68,700	0
3	+	+	4	592	0
3	0	0	4	1,215	0
8	0	+	4	29,718	0
8	+	+	4	987	0
8	0	0	4	706	0
25	0	+	2	954	2,345
25	0	+	4	4,606	9,824
25	+	+	4	239	2,566
25	0	0	4	132	355
60	0	+	4	2,393	0
60	+	+	4	42	0
60	0	0	4	108	0
60 and 3	0	+	4	13,690	24,912
60 and 3	+	+	4	1,119	11,280
60 and 3	0	0	4	1,202	5,201

* 1.5 × 10⁸ intravenously.

‡ + indicates 5 μl of late-immune serum added to each culture at outset; 0 indicates no antiserum added.

§ + indicates 2.5 × 10⁶ SRBC added to each culture at outset; 0 indicates no SRBC added.

|| Means of duplicate assays of at least four viable cultures, each seeded with 1 × 10⁷ MSC.

dilution employed with unabsorbed late-immune serum, typically had a mild enhancing effect on the response.

Routinely $5 \mu\text{l}$ of late-immune anti-SRBC mouse serum was added to the appropriate cultures to produce a final hemagglutination titer of 1:2. This invariably produced marked specific inhibition of direct PFC responses regardless of the donor's immune status (Table IV).

Indirect PFC could be shown to appear and increase in number only when the suspensions were obtained either from donor animals which received *in vivo* immunizations with SRBC between 1 and 6 wk before sacrifice, or from late-immune animals which had recently received second *in vivo* SRBC immunizations. Late-immune serum added to indirect PFC-producing cultures almost




FIG. 4. Effect on the primary *in vitro* direct PFC response when $5 \mu\text{l}$ of late-immune mouse anti-SRBC serum was added to cultures at the stated times after initiation of the cultures. Each bar represents the mean response of four to six cultures.

abolished the direct PFC response but had much less effect on the generation of indirect PFC (Table IV).

Insofar as cultures from both nonimmune and late-immune donors were similarly sensitive to antibody inhibition, the duration of this sensitive phase was assessed. We were able to confirm previous findings that the primary PFC response to SRBC *in vitro* is inhibitable by antibody only in the first 24–36 hr phase of the response (10). We also found a similar limited period of susceptibility for responses from late-immune MSC suspensions (Fig. 4).

DISCUSSION

Differences between immune and nonimmune animals cannot be solely due to simple quantitative changes suggested by Burnet's initial clonal selection hypothesis (11) if apparent qualitative distinctions of the secondary response are to be accounted for (1–5, 12–14). The immune state must reflect in addition some change in the composition of the cellular population responding to reimmunization, as experiments testing the performance of immune cell populations suggest (15–17).

8 wk after immunization with 1.5×10^8 SRBC the response of DBA/2 mice to SRBC *in vivo* is clearly distinguishable from that of closely matched mice which have not been previously given SRBC injections. In our hands three invariable and distinctive features of such a secondary response *in vivo* are: (a) inability to abrogate the response by administration of immune serum; (b) the simultaneous generation of direct and indirect PFC from the outset of the response; and (c) the presence of indirect PFC in numbers greatly exceeding those of direct PFC. The *in vitro* responses to SRBC of spleen cells from such late-immune and nonimmune mice were, however, essentially indistinguishable.

Neither late-immune nor non-immunized mice yielded spleen cell cultures in which we could detect indirect PFC responses.² There is a possibility this deficiency indicates that cells responsible for producing indirect PFC did not function well in the *in vitro* conditions. However, good indirect PFC responses occurred in cultures set up between 10 and 30 days after *in vivo* immunization. This might be more compatible with the indirect PFC response *in vitro* being dependent on a cell type which accumulates in the spleen late in the primary response but subsequently migrates. The peak potential for indirect PFC formation *in vitro* was about 20 days after primary *in vivo* immunization. This lagged considerably behind the preceding primary *in vivo* indirect PFC response, which in our system has fallen to less than 10% of its peak by the 10th day after primary immunization. Thus splenic indirect PFC content did not relate to the capacity of derived cultures for indirect PFC generation. This suggests that, if poor *in vitro* indirect PFC responses are due to the lack of a particular cell type, the cell type concerned is not the indirect PFC *per se*.

Anti-SRBC antibody essentially abolished the responses of cultures from late-immune mice but had little effect on the *in vivo* response of these animals. Such antibody also dramatically inhibits the primary *in vivo* response and the response of cultures from nonimmune mice. The action of administered antibody in cultures from late-immune and nonimmune mice appeared similar in both degree and timing; it was almost totally inhibiting if present in the first 24 hr of the *in vitro* response but was not inhibiting thereafter.

The one established difference between MSC cultures from late-immune and nonimmune donors was that the former gave higher overall responses. This quantitative difference was slight compared to that between MSC cultures from 3-day immune and nonimmunized donors. Further, we could find no evidence for any differences in the composition or properties of the *in vitro*-responding cell populations from these two sources. Such evidence was mainly sought by assessing the effect on the responses of late-immune and nonimmune cultures

² The detection of a small number of indirect PFC in primary MSC cultures has been reported with the use of heavy chain-specific antisera (18). While the sensitivity of our own assay cannot exclude the presence of a small proportion of indirect PFC, it serves to establish the presence of a deficiency in this component of the response.

when the *in vitro* antigen concentration and the spleen cell concentration were varied, which resulted in parallel changes in the responses of the two groups. In addition, the *in vitro* response of spleen cells from late-immune animals was shown to resemble that of spleen cells from nonimmune animals in its dependence on two subpopulations which could be separated by surface adherence (9).

With respect to both indirect PFC production and susceptibility to inhibition by specific antibody, responses of cultures from late-immune mice resembled the early primary *in vivo* response and the *in vitro* response of nonimmune mice. The *in vitro* response of early-immune mice appeared distinct from these and more akin to the *in vivo* secondary response. Thus spleen cell cultures taken from mice between 10 and 30 days after *in vivo* immunization not only generated indirect PFC but produced them concurrently with the production of direct PFC from the outset, in a response which was relatively unsusceptible to inhibition by the presence of anti-SRBC antibody.

An interpretation of the data is that the response to SRBC of MSC cultures from animals receiving SRBC 8 or more wk previously differs basically from the *in vivo* response of such mice, and reflects the characteristics of the cell system determining the response in MSC cultures from nonimmunized animals.

Passive immunization of nonimmune mice abolished their capacity to produce a primary *in vivo* PFC response to SRBC. However, washed spleen cells from such passively immunized animals gave a normal *in vitro* response. The procedure of putting spleen cells into culture appears to free them from the specific inhibiting effect of antibody which they would have had to contend with *in vivo*. This is compatible with the *in vitro* direct PFC response from late-immune spleen cells representing a response which is largely suppressed *in vivo* due to the continuing presence there of anti-SRBC antibody.

The *in vivo* secondary response of late-immune mice is characterized by the antibody-insuppressible generation of predominantly indirect PFC. *In vitro*, spleen cells of these mice fail to yield such a response. It is thought possible that this is due to the spleen's lacking a cell type necessary for the *in vivo* response of these mice. Such a deficiency is not present 2-3 wk after *in vivo* immunization and is rapidly corrected after *in vivo* reimmunization of late-immune animals.

It is concluded that the specific adaptation determining the immune state to SRBC involves development of a new pathway for an antibody response, and that the immune mouse also fully retains an unadapted preexisting pathway which had served for the original early primary response.

SUMMARY

The immune responses to sheep erythrocytes of mouse spleen cell suspensions from immune and nonimmune donors were compared *in vitro*. *In vivo* immunity

was only transiently reflected in vitro, and 8 wk after in vivo immunization the responses of cultures from immunized and nonimmunized mice were virtually identical. There appeared to be two mechanisms for an antibody response to sheep erythrocytes. The first was responsible for the early primary response and is unmodified in the immune animal though contributing little to subsequent in vivo responses due to its suppressibility by specific antibody. The second was expressed in the in vivo secondary response but not on in vitro challenge of spleen cells from mice immunized many weeks previously; spleen cell cultures from such immune mice, freed from the antibody of the in vivo environment, once again demonstrate a pure primary-type response.

We thank Miss Sandra Struthers for her skilled technical assistance.

BIBLIOGRAPHY

1. Glenny, A. T., and H. J. Südmersen. 1921. Notes on the production of immunity to diphtheria toxin. *J. Hyg.* **20**:176.
2. Svehag, S. E., and B. J. Mandel. 1964. The formation and properties of poliovirus-neutralizing antibody. II. 19S and 7S antibody formation: differences in antigen dose requirement for sustained synthesis, anamnesis, and sensitivity to X-irradiation. *J. Exp. Med.* **119**:21.
3. Rowley, D. A., and F. W. Fitch. 1968. Clonal selection and inhibition of the primary antibody response by antibody. *In* Regulation of the Antibody Response. B. Cinader, editor. Charles C Thomas, publisher, Springfield, Ill. 127.
4. Sinclair, N. R. St. C. 1967. A comparison of primary and secondary haemolysin responses to sheep erythrocytes in neonatally thymectomized and normal Swiss mice. A time course study of total, 19S and 7S antibody. *Immunology.* **12**:559.
5. Axelrad, M. A. 1968. Suppression of delayed hypersensitivity by antigen and antibody. Is a common precursor cell responsible for both delayed hypersensitivity and antibody formation? *Immunology.* **15**:159.
6. Mishell, R. I., and D. W. Dutton. 1967. Immunization of dissociated spleen cell cultures from normal mice. *J. Exp. Med.* **126**:423.
7. Wortis, H. H., R. B. Taylor, and D. W. Dresser. 1966. Antibody production studied by means of the LHG assay. I. The splenic response of CBA mice to sheep erythrocytes. *Immunology.* **11**:603.
8. Jerne, N. K., A. A. Nordin, and C. Henry. 1963. The agar plaque technique for recognizing antibody-producing cells. *In* Cell Bound Antibodies. B. Amos and H. Kaprowski, editors. Wistar Institute Press, Philadelphia, Pa. 109.
9. Mosier, D. E. 1967. A requirement for two cell types for antibody formation in vitro. *Science (Washington).* **158**:1573.
10. Pierce, C. W. 1969. Immune responses in vitro. II. Suppression of the immune response in vitro by specific antibody. *J. Exp. Med.* **130**:365.
11. Burnet, F. M. 1957. A modification of Jerne's theory of antibody production using the concept of clonal selection. *Aust. J. Sci.* **20**:67.
12. Farr, R. S. 1958. A quantitative immunochemical measure of the primary interaction between I*BSA and antibody. *J. Infect. Dis.* **103**:239.

13. Steiner, L. A., and H. N. Eisen. 1967. Sequential changes in the relative affinity of antibodies synthesized during the immune response. *J. Exp. Med.* **126**:1161.
14. Šterzl, J., and A. M. Silverstein. 1967. Developmental aspects of immunity. *Advan. Immunol.* **6**:337.
15. Roberts, J. C., and F. J. Dixon. 1955. The transfer of lymph node cells in the study of the immune response to foreign proteins. *J. Exp. Med.* **102**:379.
16. Gowans, J. L., and D. D. McGregor. 1965. The immunological activities of lymphocytes. *Progr. Allergy.* **9**:1.
17. Gowans, J. L., and J. W. Uhr. 1966. The carriage of immunological memory by small lymphocytes in the rat. *J. Exp. Med.* **124**:1017.
18. Pierce, C. W., and B. M. Johnson. 1970. The development of primary γ G plaque-forming cell responses in vitro. *Fed. Proc.* **29**:571. (Abstr.)